HPV vaccine safety surveillance HPV vaccine safety surveillance data From January 2018 a new HPV vaccine, Gardasil9®, is being funded under the National Immunisation Program. AusVaxSafety is monitoring the safety of HPV vaccine in 11- to 14-year olds. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here. Last updated 21/02/2020 42,774 Parents/carers responded to an SMS about their child’s health a few days after their HPV vaccinations. 91.3% reported no adverse events 91.3% reported no adverse events 8.7% reported any adverse event, including... 0.6% who reported taking their child to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 3,736 parents/carers reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived.
